Formulations and methods of use for alpha connexin C-terminal (ACT) peptides
This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.
1. A method of treating a chronic wound in a subject, comprising administering to the subject a topical formulation comprising at least one alpha connexin polypeptide in addition to standard of care therapy, wherein the at least one alpha connexin polypeptide comprises the carboxy terminal-most 4 to 30 contiguous amino acids of an alpha connexin, or a conservative variant thereof, wherein the standard of care therapy is pressure off-loading, wherein the chronic wound is healed at a faster rate and/or increased frequency than achieved with standard of care therapy alone, wherein the method does not comprise administration of an anti-inflammatory active agent that is not an alpha connexin polypeptide, wherein the chronic wound is an ulcer, and wherein the formulation further comprises hydroxyethylcellulose gel.
2. The method of claim 1 , wherein the alpha connexin polypeptide is connexin 37, connexin 40, connexin 43, or connexin 45.
3. The method of claim 1 , wherein the alpha connexin polypeptide is linked at its amino terminus to a cellular internalization transporter.
4. The method of claim 3 , wherein the cellular internalization transporter is an antennapedia sequence.
5. The method of claim 1 , wherein the formulation comprises a polypeptide comprising the amino acid sequence of SEQ ID NO: 9.
6. The method of claim 1 , wherein the chronic wound is a lower extremity ulcer.
7. The method of claim 1 , wherein the chronic wound is selected from the group consisting of venous leg ulcers, diabetic foot ulcers, and pressure ulcers.
8. The method of claim 1 , wherein the formulation is administered in a dosing regimen comprising topical administration at day 0, day 3, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 11, and week 12.
9. The method of claim 1 , wherein the alpha connexin polypeptide is present in the formulation at a concentration of about 20 μM to about 200 μM.
10. The method of claim 1 , wherein the alpha connexin polypeptide is present in the formulation at a concentration of about 100 μM.
11. The method of claim 1 , wherein the standard of care therapy further comprises a non-adherent dressing extending 0.5 inches beyond the ulcer perimeter and inflamed skin margins.
12. The method of claim 1 , wherein the method does not comprise administration of an active agent that is not an alpha connexin polypeptide.